

## Anti-LAG-3 [C9B7W] VivopureX 100 mg Ab01295-2.3-VXB

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG2a, [Fc Silent™](#), Kappa

**Clone Number:** C9B7W

**Alternative Name(s) of Target:** CD223; LAG3; Lymphocyte activation gene 3 protein

**UniProt Accession Number of Target Protein:** Q61790

**Published Application(s):** Blocking, IP, FC

**Published Species Reactivity:** Mouse

**Immunogen:** This antibody was raised by immunising Lewis rats with a murine LAG-3:Ig fusion protein.

**Specificity:** This antibody is specific for an epitope in the D2 domain of murine LAG-3.

**Application Notes:** This antibody has been used in flow cytometric analysis of splenocytes (Workman et al, 2005), T cell hybridomas expressing wild-type or chimeric CD4:mouse LAG-3 (Workman et al, 2002) and CD4+ regulatory T cells (Chien et al, 2017). It has also been used in immunoprecipitation analysis of murine T hybridoma 3A9 cells transduced with murine LAG-3 (Li et al, 2004). This antibody blocks LAG-3 function in vitro, inhibiting antigen-induced IL-2 production in LAG-3-expressing T cell hybridomas, but does not block LAG-3:MHC class II interaction (Workman et al, 2002). Treatment with this antibody also blocks LAG-3 function in vivo, leading to accelerated homeostatic expansion of WT T cells (Workman et al, 2005). Administration of this LAG-3-blocking antibody, in combination with PD-L1 blockade, synergistically improves the survival of lymphodepleted myeloma-bearing mice (Jing et al, 2015).

**Antibody First Published in:** Workman et al. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3) Eur J Immunol. 2002 Aug;32(8):2255-63 [PMID:12209638](#)

**Note on publication:** Describes the original generation of this antibody, and its characterisation.

## Product Form

**Size:** 100 mg VivopureX products are produced at high purity (>98%), low endotoxin (<0.5 EU/mg) and are formulated without preservatives. These antibodies are chimerized to have an Fc domain matching their target species to reduce immunogenicity and give you the optimal effector function for your experiment. As

a result VivopureX products are the ideal choice for in vivo research applications.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** All VivopureX products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense under sterile conditions. Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:**  $\geq 1$ mg (see vial label for exact conc)

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.